Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline
Financing Co-Led by Frazier Life Sciences and Deep Track Capital, with Janus Henderson Investors and Logos Capital Participating December 03, 2024 06:30 AM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a clinical-stage biopharmaceutical…